Anti-CD47 Agent Boosts Macrophage Activity in NHL
- PMID: 30464001
- DOI: 10.1158/2159-8290.CD-NB2018-155
Anti-CD47 Agent Boosts Macrophage Activity in NHL
Abstract
The anti-CD47 drug Hu5F9-G4, also known as 5F9, in combination with the anti-CD20 therapy rituximab, may be a promising treatment for some forms of non-Hodgkin lymphoma because it allows macrophages to recognize and attack cancer cells. In a phase Ib trial testing the combination, patients with relapsed/refractory diffuse large B-cell lymphoma or follicular lymphoma had an objective response rate of 50% and few side effects.
©2019 American Association for Cancer Research.
Comment on
-
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315. N Engl J Med. 2018. PMID: 30380386 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials